Amanote Research
Register
Sign In
Adjuvant Rituximab, a Potential Treatment for the Young Patient With Graves Hyperthyroidism (RiGD): Study Protocol for a Single-Arm, Single-Stage, Phase II Trial
Yearbook of Paediatric Endocrinology
doi 10.1530/ey.16.3.13
Full Text
Open PDF
Abstract
Available in
full text
Date
September 12, 2019
Authors
Cole M
Hynes AM
Howel D
Hall L
Abinun M
Allahabadia A
Barrett T
Boelaert K
Drake AJ
Dimitri P
Kirk J
Zammitt N
Pearce S
Cheetham T
Publisher
Bioscientifica
Related search
Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer
Clinical Breast Cancer
Cancer Research
Oncology
Single-Arm Phase II Trial Design Under Parametric Cure Models
Pharmaceutical Statistics
Statistics
Probability
Pharmacology
Adjuvant Rituximab Treatment for Pemphigus: A Retrospective Study of 45 Patients at a Single Center With Long-Term Follow Up
Journal of Dermatology
Dermatology
Medicine
Meglumine Antimoniate Intralesional Infiltration for Localised Cutaneous Leishmaniasis: A Single Arm, Open Label, Phase II Clinical Trial
Memorias do Instituto Oswaldo Cruz
Medicine
Microbiology
Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer With Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02)
Frontiers in Oncology
Cancer Research
Oncology
Comparative Effectiveness of Treatment Choices for Graves' Hyperthyroidism: A Historical Cohort Study
Thyroid
Medicine
Endocrinology
Metabolism
Diabetes
Onset, Longevity, and Patient Satisfaction With incobotulinumtoxinA for the Treatment of Glabellar Frown Lines: A Single-Arm, Prospective Clinical Study
Clinical Interventions in Aging
Medicine
Gerontology
Geriatrics
Colorectal Liver Metastatic Disease: Efficacy of Irreversible Electroporation—a Single-Arm Phase II Clinical Trial (COLDFIRE-2 Trial)
BMC Cancer
Cancer Research
Oncology
Genetics
A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma
Annals of Surgery
Surgery
